

Claim 5, line 1, delete "any preceding claim" and insert --claim 1--.

Claim 6, line 1, delete "any preceding claim" and insert --claim 1--.

Claim 7, line 1, delete "any preceding claim" and insert --claim 1--.

Claim 8, line 1, delete "any preceding claim" and insert --claim 1--.

Claim 10, line 1, delete "or 9".

Claim 12, line 1, delete "any of claims 8 to 10" and insert --claim 8--.

Claim 13, line 1, delete "any preceding claim", and insert --claim 1--.

Claim 14, line 1, delete "any preceding claim", and insert --claim 1--.

Claim 16, line 1, delete "or 15".

Claim 19, line 1, delete "any of claims 1 to 17", and insert --claim 1--.

Claim 22, line 1, delete "or 21".

Claim 23, line 1, delete "any of claims 1 to 17", and insert --claim 1--.

Claim 29, line 1 delete "27 or 28".

Claim 34, line 1, delete "or 33".

Claim 37, lines 1 and 2, delete "any of claims 1 to 24" and insert --claim 1--.

Claim 39, line 3, delete "any of claims 1 to 24", and insert --claim 1--.

Claim 41, line 2, insert --, said composition-- after "activation".

Claim 42, line 2, insert --, said method-- after "activation".

Claim 44, line 2, insert --, said composition-- after "activation"; and

lines 3 and 4, delete "any of claims 20 to 22", and insert --claim 20--.

Claim 45, line 3, delete "any one of claims 20 to 22" and insert --claim 20--.

Claim 47, line 1, insert --, said composition-- after "disorders"; and
line 2, delete "or 24".

Claim 48, line 3, delete "or 24".

Please add the following claims:

-- 50. A pharmaceutical composition for treating thrombotic disorders, said composition comprising a therapeutically effective amount of a derivative according to claim 24 and a pharmaceutically acceptable carrier or excipient.

51. A method of treating thrombotic disorders, comprising administering to a subject in need of such treatment a therapeutically effective amount of a derivative according to claim 24.

52. A peptidic membrane binding element derivatised according to claim 32, wherein the peptide has

(A) an amino acid sequence selected from the group consisting of (i) DGPKKKKKKSPSKSSG, (ii) GSSKSPSKKKKKPGD, (iii) SPSNETPKKKKKRFSFKKSG, (iv) DGPKKKKKKSPSKSSK and (v) SKDGKKKKKS GTK, wherein the N-terminus is on the left, and

*Att
conced.
Sub B2(e)*

(B) a fatty acid N-acyl group of 8 to 18 methylene units at the N-terminus or at an ϵ -amino group of a lysine residue of the peptide. --

CONFIDENTIAL INFORMATION - THIS PAGE IS UNCLASSIFIED